ReviewChemistry (Weinheim an der Bergstrasse, Germany)2026
Catalytic Amyloids: Turning Fibrils Into Biocatalysts.
Review in Chemistry (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Less is more: miniaturized heme enzymes with broad reactivity.Chemical science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Amyloids have been regarded as the pathological entities behind neurodegenerative diseases for a long time. The discovery that they also play physiological roles together with their ability to form stable and ordered scaffolds opened the door for their applications in different fields. In this context, catalytic amyloids have emerged as a new class of nanomaterials, merging the efficiency of enzymes with the robustness of heterogeneous catalysts. Indeed, these systems exploit the self-assembly properties of amyloids while mimicking enzymatic functions by exposing catalytic moieties on their surface. In this review, we first provide an overview of the structural and functional properties of natural amyloids and their application in nanotechnology. Then, we survey the current state of art in the development of catalytic amyloids, based on bioinspired or de novo designed sequences. In both cases, the incorporation of specific functional groups provides the fibrils with catalytic functions. Finally, we illustrate the use of amyloid fibrils as platforms for enzyme immobilization. All the selected examples highlight the power of bridging amyloid structures and catalytic activities to shape innovative nanomaterials toward demanding needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.